Thank you to our speakers, sponsors, and delegates who joined us in Boston for the summit! If you are interested in the 2025 event, please get in touch at info@hansonwade.com
Select the Optimal Combination Partner, Utilize Biomarkers, and Identify Novel Targets to Overcome DDR Inhibitor Resistance & Improve Patient Stratification to Supercharge the Next Wave of DDR Inhibitors with Lower Toxicities
Making Strides in Targeting PARP, ATR, ATM, WEE1 & POLθ
AstraZeneca and Merck are at the forefront of DDR inhibitor development, focusing on next-generation PARP inhibitors and innovative combination therapies. At the same time, Roche and Novartis are pushing their own DDR-targeting pipelines, exploring emerging targets such as USP1 and WRN – these combined efforts are making DDR inhibitor drug development an increasingly dynamic and transformative area.
Additionally, biotechs like Artios Pharma and Repare Therapeutics are expanding the field with cutting-edge research and clinical programs, using innovative platforms to understand cancer biology, discover novel DDR targets, and identify patients most likely to benefit from the treatments.
In light of these advancements, the 8th Annual DDR Inhibitors Summit, returned to Boston in January, as the community hotspot for biopharma drug developers and researchers to collaborate on advancing DDR therapeutics.
We joined 100+ experts from discovery, preclinical, translational, regulatory, and clinical roles as they united to harness the potential of DDR inhibitors for cancer treatment and enhance patient outcomes.
What was New in 2025?
 |
Hear From Leading Voices: Insight from industry leaders such as Lisa Mahnke (President, Board Member, Chief Executive & Medical Officer, Nerviano Medical Sciences), Harry Raftopoulos (Senior Vice President, Clinical Research, Head of Oncology, Eikon Therapeutics), and Kirk Tanner (Chief Scientific Officer, National Brain Tumor Society) sharing their experiences in advancing DDR therapeutics |
|
Evaluate Novel DDR Pathways: Presentations on innovative approaches like Eisbach Bio’s first-in-class allosteric inhibitor of ALC1, ForX Therapeutics’ potent PARG inhibitor, and CTX-439, and Chordia Therapeutics’ first-in-class CDK12 inhibitor, highlighting their potential in clinical applications |
|
Explore Innovative Drug Discovery & Development: Insights on AI-powered methodologies for identifying synthetic lethal DDR targets from Insilico Medicine and assessing the patient-selection capabilities of of Allarity Therapeutic’s Drug Response Predictor (DRP) diagnostic |
2025's World-Class Speaker Faculty Included:
Mark O’Connor
Chief Scientist, Oncology R&D, Head of the DNA Damage Response Strategic Biology Area
AstraZeneca
Timothy Yap
Head of Clinical Development & VP, Therapeutics Discovery Division & Prof., Department of Investigational Cancer Therapeutics
MD Anderson Cancer Center
Wendy Fantl
Director & Head, Systems- Level Translational Discovery, Discovery Sciences, Biomedical Research
Novartis
Hear From Our DDR Peers:
“The opportunity to network with industry and academic colleagues, focused discussions and round tables, presence of key companies in the DDR space.” - Lucas Velloso, Lifecycle Leader, Roche
“Great opportunity to network in a small environment with key experts." - Sonia Rodrigues, Executive Director & Head of Haematology Global Regulatory Affairs, AstraZeneca
Previously Attending Companies Included:
2025 Partners
View Upcoming Events in the Series Here:
